Syracuse

Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial

Archive ouverte

Kotb, Shady | Detappe, Alexandre | Lux, François | Appaix, Florence | Barbier, Emmanuel, L. | Tran, Vu-Long | Plissonneau, Marie | Gehan, Hélène | Lefranc, Florence | Rodriguez-Lafrasse, Claire | Verry, Camille | Berbeco, Ross | Tillement, Olivier | Sancey, Lucie

Edité par CCSD ; Ivyspring International Publisher -

International audience. Nanoparticles containing high-Z elements are known to boost the efficacy of radiation therapy. Gadolinium (Gd) is particularly attractive because this element is also a positive contrast agent for MRI, which allows for the simultaneous use of imaging to guide the irradiation and to delineate the tumor. In this study, we used the Gd-based nanoparticles, AGuIX®. After intravenous injection into animals bearing B16F10 tumors, some nanoparticles remained inside the tumor cells for more than 24 hours, indicating that a single administration of nanoparticles might be sufficient for several irradiations. Combining AGuIX® with radiation therapy increases tumor cell death, and improves the life spans of animals bearing multiple brain melanoma metastases. These results provide pre-clinical proof-of-concept for a phase I clinical trial.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion